misonidazole has been researched along with Disease Exacerbation in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Andreev, DN; Bellaye, PS; Bonniaud, P; Bouchard, A; Cochet, A; Collin, B; Frenay, J; Goirand, F; Guillemin, M; Helbling, A; Kucheryavy, YA; Mayev, IV; Moreau, M; Mothes, C; Oudot, A; Tanguy, J | 1 |
| Badimon, JJ; Fayad, ZA; Fuster, V; Izquierdo-Garcia, D; Mateo, J | 1 |
| Fink, JR; Krohn, KA; Mankoff, DA; McLaughlin, LJ; Muzi, JP; Muzi, M; O'Sullivan, JN; Peterson, LM; Rajendran, JG | 1 |
| Andrzejewski, P; Baltzer, P; Georg, D; Georg, P; Grimm, C; Helbich, TH; Karanikas, G; Mitterhauser, M; Pinker, K; Poetter, R; Polanec, SH; Polterauer, S; Sturdza, A; Wadsak, W | 1 |
| Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C | 1 |
| Astner, ST; Bayer, C; Maftei, CA; Shi, K; Vaupel, P | 1 |
| Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S | 1 |
| Chambers, BR; Donnan, GA; Kazui, S; Markus, R; Read, S; Reutens, DC; Sachinidis, JI; Tochon-Danguy, HJ; Wright, P | 1 |
| Donnan, GA; Kazui, S; Markus, R; Pearce, DC; Read, S; Reutens, DC; Sachinidis, JI; Tochon-Danguy, HJ; Wright, P | 1 |
| Donnan, GA; Falcao, AL; Howells, DW; Koga, M; Markus, R; Read, SJ; Reutens, DC; Sachinidis, J; Tochon-Danguy, H | 1 |
| Hicks, RJ; Toner, GC | 1 |
| Adamsen, TC; Krohn, KA; Link, JM; Muzi, M; O'Sullivan, F; Rajendran, JG; Rockhill, JK; Rostomily, RC; Silbergeld, DL; Spence, AM; Swanson, KR; Swanson, PE; Yagle, KJ | 1 |
| Abbott, DF; Bladin, CF; Chan, JG; Donnan, GA; Egan, GF; Hirano, T; Markus, R; McKay, WJ; Read, SJ; Sachinidis, JI; Scott, AM; Tochon-Danguy, HJ | 1 |
2 review(s) available for misonidazole and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Abdominal Pain; Animals; Biomarkers; Disease Progression; Dyspepsia; Fluorodeoxyglucose F18; Humans; Hypoxia; Idiopathic Pulmonary Fibrosis; Mice; Misonidazole; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Prevalence; Radiopharmaceuticals; Sleep Wake Disorders | 2021 |
PET for sarcomas other than gastrointestinal stromal tumors.
Topics: Biopsy; Dideoxynucleosides; Disease Progression; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Misonidazole; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Sarcoma; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2008 |
2 trial(s) available for misonidazole and Disease Exacerbation
| Article | Year |
|---|---|
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain; Brain Ischemia; Cell Survival; Disease Progression; Female; Fluorine Radioisotopes; Humans; Hypoxia, Brain; Infarction, Middle Cerebral Artery; Male; Middle Aged; Misonidazole; Predictive Value of Tests; Stroke; Tomography, Emission-Computed | 2003 |
9 other study(ies) available for misonidazole and Disease Exacerbation
| Article | Year |
|---|---|
Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using ¹⁸F-fluoromisonidazole positron emission tomographic imaging.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Disease Models, Animal; Disease Progression; Fluorine Radioisotopes; Hypoxia; Male; Misonidazole; Positron-Emission Tomography; Rabbits; Radiation-Sensitizing Agents; Reproducibility of Results; Severity of Illness Index | 2014 |
18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
Topics: Adult; Aged; Aged, 80 and over; Aorta; Brain Neoplasms; Cerebellum; Disease Progression; Female; Heart; Humans; Hypoxia; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neoplasms; Oxygen; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Tissue Distribution; Treatment Outcome | 2015 |
Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Tumor Burden; Uterine Cervical Neoplasms | 2016 |
Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.
Topics: Acute Disease; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chronic Disease; Disease Progression; Head and Neck Neoplasms; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Mice; Misonidazole; Multimodal Imaging; Positron-Emission Tomography; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Transplantation, Heterologous | 2011 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2012 |
Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Hypoxia-Ischemia, Brain; Male; Middle Aged; Misonidazole; Prognosis; Recovery of Function; Severity of Illness Index; Time Factors; Tomography, Emission-Computed | 2004 |
The resistance to ischemia of white and gray matter after stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Brain Mapping; Cerebral Infarction; Disease Progression; Female; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Stroke | 2004 |
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Regression Analysis | 2008 |
The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain; Disease Progression; Female; Humans; Hypoxia-Ischemia, Brain; Male; Misonidazole; Stroke; Time Factors; Tomography, Emission-Computed | 2000 |